Highlighted Events
Praxis Precision Medicines Announces Plan to Start PRAX-222 (formerly RC-222) EMBRAVE Clinical Study following FDA clearance
January 2023
Invitae’s Real World Ciitizen Data Utilized in PRAX-222 (formerly RC-222) IND Filing
September 2022
PRAX-222 (formerly RC-222)Receives Rare Pediatric Disease and Orphan Drug Designation
January 2021
RogCon Development Partner Praxis Precision Medicines to Present on PRAX-222 (formerly RC-222) Program at SCN2A Family Virtual Conference
September 2020